Waverley Pharma, Inc. (WAVE) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Waverley Pharma, Inc. has changed its score on 27 Nov 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 12.96% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.81

The company has declared Negative results for the last 8 consecutive quarters

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 1 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.32

Return on Equity

18.80%

Price to Book

-0.51

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

33.33%

6 Months

0.0%

1 Year

0.0%

2 Years

-42.86%

3 Years

-50.0%

4 Years

-76.47%

5 Years

-85.71%

Waverley Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

2.04%

EBIT Growth (5y)

12.96%

EBIT to Interest (avg)

-0.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.32

Sales to Capital Employed (avg)

0.52

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.63

EV to EBIT

-4.17

EV to EBITDA

-4.17

EV to Capital Employed

4.17

EV to Sales

3.33

PEG Ratio

Dividend Yield

ROCE (Latest)

-22.29%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -20.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 100.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "26.50%",
          "val2": "-50.10%",
          "chgp": "7.66%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 25.00% vs -66.67% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 59.09% vs -214.29% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.40",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.90",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "-2.20",
          "chgp": "59.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,564.20%",
          "val2": "-2,922.20%",
          "chgp": "135.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.40

Operating Profit (PBDIT) excl Other Income

0.00

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.00

Operating Profit Margin (Excl OI)

26.50%

-50.10%

7.66%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -20.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 100.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.50

0.40

25.00%

Operating Profit (PBDIT) excl Other Income

-0.70

-0.90

22.22%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

-0.90

100.00%

Consolidate Net Profit

-0.90

-2.20

59.09%

Operating Profit Margin (Excl OI)

-1,564.20%

-2,922.20%

135.80%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 25.00% vs -66.67% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 59.09% vs -214.29% in Dec 2023

All Annual Results

Company CV

About Waverley Pharma, Inc.

Waverley Pharma, Inc.

Pharmaceuticals & Biotechnology

Waverley Pharma Inc is a Canada-based company engaged in Biotechnology & Medical Research sector.The Company is focused on developing and commercializing Safe and Effective Small Molecules for Treatment of Cancer. Waverley Pharma is working in collaboration with a Indian conglomerate based in Mumbai to develop products for the treatment of cancer. Two of the lead products under developments are: WAV-101: WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications; WAV-102 is also an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. The Company has signed an agreement with Omgene Life Sciences for the development of another generic anti-cancer product WAV-103.

Company Coordinates

Company Details

4-1250 Waverley St , WINNIPEG MB : R3T 6C6

Tel:

http://www.waverleypharma.com/

Registrar Details